December 6, 2024
Major Australian breakthrough could revolutionise hypertension treatment
Read more
Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Read morePhase III trial results of novel triple combination pill for hypertension published in The Lancet
Read moreCerta Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Read moreNRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Read moreENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
Read moreMyricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
Read morePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read moreEnhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
Read moreMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
Read moreBrandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease
Read moreNew Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
Read moreGlyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
Read moreCUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program
Read moreNasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
Read moreComing in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
Read moreAravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile
Read moreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Read moreAzura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
Read moreCerta Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Read morePathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
Read moreAzura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Read moreBrandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Read moreAzura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Read moreMedisanté and George Medicines collaborate to bring Internet of Things (IoT) data collection to decentralised Phase III trial of single-pill triple combination candidate to treat hypertension
Read moreVaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration
Read moreAustralian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials
Read moreGlyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Read moreAustralian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions
Read moreParkinson’s patients benefit from revolutionary watch on the NHS to manage care at home
Read morePolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Read moreGlyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Read moreAllay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform
Read more$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments
Read moreIndustry-led leadership programme launched to support women into more top science and innovation roles
Read moreOncoRes Medical receives $150,000 funding boost from Western Australian Government
Read moreMyricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
Read moreAzura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Read moreVaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Read moreVaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Read moreQUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats
Read more$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease
Read morePerth tech joint-winner in global finals for international start-up competition
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
